Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $93.14.

A number of research analysts have recently issued reports on KNSA shares. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, September 30th. They set an “overweight” rating and a $87.00 price target for the company. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. lifted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th.

Insider Buying and Selling

In other news, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the sale, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at $2,333,678.60. This trade represents a 13.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KNSA. Park Avenue Securities LLC lifted its holdings in Kiniksa Pharmaceuticals International by 7.4% in the third quarter. Park Avenue Securities LLC now owns 15,829 shares of the company’s stock valued at $1,181,000 after acquiring an additional 1,095 shares during the period. Sowell Financial Services LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth $3,039,000. Sterling Capital Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 911.4% during the 3rd quarter. Sterling Capital Management LLC now owns 1,507 shares of the company’s stock worth $112,000 after purchasing an additional 1,358 shares during the period. Curry Webb Wealth Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth $29,000. Finally, Robeco Institutional Asset Management B.V. purchased a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $1,046,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $72.98 on Tuesday. The company has a market cap of $5.69 billion, a P/E ratio of 75.24 and a beta of 0.04. Kiniksa Pharmaceuticals International has a one year low of $35.20 and a one year high of $84.06. The firm has a fifty day moving average of $78.03 and a two-hundred day moving average of $59.00.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting the consensus estimate of $0.30. The company had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. As a group, equities analysts predict that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.